



UNIVERSITI PUTRA MALAYSIA

**GENERATION OF A PANEL OF MONOCLONAL ANTIBODIES
AGAINST THE HAEMAGGLUTININ-NEURAMINIDASE
GLYCOPROTEIN OF NEWCASTLE DISEASE VIRUS STRAIN AF2240**

LEE LIN KIAT.

FBSB 2005 12

**GENERATION OF A PANEL OF MONOCLONAL ANTIBODIES AGAINST
THE HAEMAGGLUTININ-NEURAMINIDASE GLYCOPROTEIN OF
NEWCASTLE DISEASE VIRUS STRAIN AF2240**


By

LEE LIN KIAT

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfilment of the Requirements for the Degree of Master of Science**

September 2005





Dedicated to Dad, Mom and Christine

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in
fulfilment of the requirement for the degree of Master of Science

**GENERATION OF A PANEL OF MONOCLONAL ANTIBODIES
AGAINST THE HAEMAGGLUTININ-NEURAMINIDASE
GLYCOPROTEIN OF NEWCASTLE DISEASE VIRUS STRAIN AF2240**

By

LEE LIN KIAT

September 2005

Chairperson: Professor Datin Khatijah Mohd. Yusoff, PhD

Faculty: Biotechnology and Biomolecular Sciences

The Malaysian velogenic-viscerotropic Newcastle disease virus (NDV) strain AF2240 is responsible for high mortality and morbidity. Monoclonal antibodies (mAbs) have been known to be useful in the identification of NDV due to their binding specificity, their homogeneity and their ability to be produced in unlimited quantities. It is, however, very difficult to obtain mAbs which are specific to NDV commercially. Therefore, this project is to develop mAbs against the local NDV strain AF2240. This velogenic-viscerotropic viral strain is a reference strain that has often been used for vaccine development.

Hybridoma cells were created by fusing NDV-hyperimmunised Balb/c splenocytes with Sp2/0-Ag14 (Sp2) myeloma cells using polyethylene glycol with the molecular weight of 1450 (PEG 1450). Positive clones were screened by ELISA. High titre producing clones were selected from a series of limiting dilutions. MAbs from stable hybridomas were further characterised by western

blot analysis, haemagglutination-inhibition test (HI) and haemolysis-inhibition test (HLI).

Eight hybridoma cell lines producing mAbs against the haemagglutinin-neuraminidase (HN) glycoprotein of NDV strain AF2240 were generated. Isotyping showed that mAbs 1B9, 2D6 and 9D7 were IgG1, mAbs 1D5, 5A10 and 5F10 were IgG2a and mAbs 2G3 and 5E10 were IgG3. Kappa (κ) light chains were found in all mAbs. They can be divided into two groups: (1) mAbs 1D5, 5A10 and 5E10 which recognised conformational and linearised epitopes and (2) mAbs 1B9, 2D6 and 9D7 which recognised only conformational epitopes. All mAbs showed positive results in the HI test but not HLI test confirming that they were specific to the HN protein and not the fusion (F) protein.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia
sebagai memenuhi keperluan untuk ijazah Master Sains

**PENGENERASIAN SATU PANEL ANTIBODI MONOKLONAL
TERHADAP GLIKOPROTEIN HEMAGGLUTININ-NEURAMINIDASE
VIRUS PENYAKIT NEWCASTLE STRAIN AF2240**

Oleh

LEE LIN KIAT

September 2005

Pengerusi: Profesor Datin Khatijah Mohd. Yusoff, PhD

Fakulti: Bioteknologi dan Sains Biomolekul

Virus penyakit sampar ayam atau virus penyakit Newcastle (NDV) strain tempatan AF2240 menyebabkan kematian yang tinggi. Antibodi monoklonal (mAb) sudah diketahui dengan kegunaannya dalam pengenalan NDV berasaskan spesifikasi ikatan, keseragaman dan keupayaan dihasilkan dalam jumlah yang banyak. Namun demikian, mAb susah diperolehi secara komersil. Maka, projek ini bertujuan menghasilkan mAb terhadap NDV tempatan. Virus strain velogenic-viscerotropic ini menjadi strain rujukan yang kerap digunakan dalam penghasilan vaksin.

Sel hibridoma telah dihasilkan melalui pergabungan sel limfosit Balb/c yang telah dipertingkatkan immunisasinya terhadap NDV dengan sel miloma Sp2/0-Ag14 (Sp2) menggunakan polietilen gliko dengan berat molekul 1450 (PEG 1450). Klon positif diasai daripada teknik ELISA. Klon yang menghasilkan titer tinggi akan dipilih daripada satu siri pencairan terhadap MAb daripada hibridoma

yang stabil akan dicirikan secara lanjutan melalui analisis 'western blot', ujian penghalangan hemagglutinin (HI) dan ujian penghalangan hemolisis (HLI).

Lapan rangkaian sel hibridoma yang menghasilkan mAb terhadap NDV strain AF2240 glikoprotein hemagglutinin-neuraminidase (HN) telah digenerasikan. Pengkelasan antibodi telah menunjukkan mAb 1B9, 2D6 dan 9D7 dari sub-kelas IgG1, mAb 1D5, 5A10 dan 5F10 dari sub-kelas IgG2a dan mAb 2G3 dan 5E10 dari sub-kelas IgG3. Semua mAb mempunyai rantai ringan jenis kappa (κ). Ia juga boleh dibahagikan kepada dua kumpulan: (1) mAb 1D5, 5A10 dan 5E10 yang mengenali epitop konformasi and linear serta (2) mAb 1B9, 2D6 dan 9D7 yang mengenali epitop konformasi sahaja. Semua mAb menunjukkan keputusan positif terhadap ujian HI dan sebaliknya untuk ujian HLI bagi mengesahkan mAb adalah spesifik terhadap protein HN dan bukan protein fusion (F).

ACKNOWLEDGEMENTS

I would like to express my sincere gratitude and appreciation to my supervisors Professor Datin Dr. Khatijah Mohd. Yusoff and Professor Dr. Abdul Manaf Ali for their valuable advice, technical guidance and encouragement.

Special thanks to the staff especially Mr. Karim, Mr. Hussain, Mr. Ibrahim, Mr. Zamros and Mdm. Sharipah from Department of Microbiology and Department of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, UPM. Not forgetting, Mr. Othman for his excellent job in maintaining the animal house.

I wish to acknowledge the guidance and support from Associate Professor Dr. Tan Wen Siang, Dr. Majid Eshahgi, Dr. Heilly Chong, Dr. Michael Aigner, Dr. Wong Sing King, Dr. Lim Yang Mooi and Dr. Kho Chiew Ling; my lab seniors; Firoozeh, Swee Tin, Raha, Geok Hun, Eddie, Lalita, Nazrien, Onie, Rafidah, Riha, Suhana, Thong Chuan, Yan Peng and Zul; my colleagues; Budy, Ina, Kah Fai, Kie Hie, Max, Mokrish, Pala, Taznim, Wani and Wawa.

My gratitude also goes out to my friends; Ainon, Bok Hui, Chin Woi, Judy, Han Koh, Hazalina, Keng Fei, Kim Seng, Lee Kheng, Lih Ling, May Ling, Michelle, Sheau Wei, Tiong San and Wattti. Support from Mdm. Maria Chew (Culture Lab), Mr. W. H. Looi (Roche Diagnostic), Mr. C. H. Ti (Trans Techno), Ms.

Angie Yip (Research Instruments) and Mr. C. W. Lye (Biodiagnostic) are always appreciated.

I am indeed indebted to Janet Loh, my buddies Amos and Leslie for sharing their knowledge and experience with me. My parents and Christine for their unconditional sacrifice and love.

I wish to extend my appreciation to everyone, although not individually named here, who had contributed directly or indirectly to my project and thesis. Finally, I would like to thank the Ministry of Science, Technology and Innovation of Malaysia (MOSTI) for providing me the PASCA scholarship and IRPA grant no. 01-02-04-003 BTK/ER/006 for supporting this study.

Without all of you, it would not be possible for me to complete my project and thesis. Thank you all for your support and unconditional love. May God bless you all for your kindness.

TABLE OF CONTENTS

DEDICATION	Page ii
ABSTRACT	iii
ABSTRAK	v
ACKNOWLEDGEMENTS	vii
APPROVAL	ix
DECLARATION	xi
LIST OF TABLES	xiv
LIST OF FIGURES	xv
LIST OF ABBREVIATIONS	xvi

CHAPTER

1	INTRODUCTION	1
2	LITERATURE REVIEW	
	2.1 Basic Concepts in Hybridoma Technology	
	2.1.1 Somatic Cell Hybridisation	4
	2.1.2 Immunisation Strategies	6
	2.1.3 Cell Fusion	8
	2.1.4 Hybridoma Selection	11
	2.1.5 Screening	13
	2.1.6 Cloning of Hybridomas	15
	2.1.7 Cryopreservation of Hybridomas	16
	2.1.8 Scale Up Production of mAbs	17
	2.1.9 Antibody Purification	18
	2.2 Application of Monoclonal Antibodies	
	2.2.1 Research and Diagnostic Applications	19
	2.2.2 Therapeutic Applications	21
	2.3 Newcastle Disease Virus	23
3	METHODOLOGY	
	3.1 Source of Viruses and Cell	30
	3.2 Source of Chemicals and Biochemicals	31
	3.3 Virus Cultivation and Purification	31
	3.4 Viral Profiles	
	3.4.1 Bradford Assay	32
	3.4.2 Haemagglutination (HA) Test	33
	3.4.3 SDS-PAGE Protein Profile	34
	3.5 Myeloma Cultivation	35
	3.6 Immunisation	
	3.6.1 Immunogen Preparation and Immunisation	36
	3.6.2 Antibody Titre	36
	3.7 Hybridoma Development	
	3.7.1 Splenectomy	37
	3.7.2 Cell Fusion	38
	3.7.3 Hybridoma Selection	39

3.7.4	Screening for Antibody Producing Hybridoma	39
3.7.5	Limiting Dilution	40
3.7.6	Expansion and Cryopreservation	41
3.8	Ascites Fluid and Purification	
3.8.1	Ascites Production	41
3.8.2	Antibody Purification and Storage	42
3.8.3	Antibody Concentration Determination	43
3.8.4	Antibody Titre Determination	43
3.9	Characterisation of Monoclonal Antibodies	
3.9.1	Antibody Isotyping Determination	43
3.9.2	Heavy and Light Chains Determination	44
3.9.3	Immunoblot Analysis	45
3.9.4	Haemagglutination-Inhibition (HI) Test	46
3.9.5	Haemolysis-Inhibition (HLI) Test	47
3.9.6	Cross-Reactivity Test	47
4	RESULTS	
4.1	Production of Hybridoma	49
4.2	Characterisation of Selected Hybridomas	
4.2.1	Isotyping	55
4.2.2	Antibody Purity	55
4.2.3	Immunoblotting against HN Glycoprotein	59
4.2.4	Haemagglutination-Inhibition and Haemolysis-Inhibition Tests	61
4.2.5	Cross-Reactivity Test for NDV Inter-Strains	61
4.2.6	Cross-Reactivity Test for Avian Viruses	63
5	DISCUSSION	
5.1	Production of Monoclonal Antibodies against HN Glycoprotein	66 71
5.2	Characterisation of Selected Hybridomas	
6	CONCLUSION	76
	REFERENCES	77
	BIODATA OF THE AUTHOR	93

LIST OF TABLES

Table		Page
2.1	Suggested possible immunisation routes and doses of immunogen for mice	7
2.2	Post-fusion selection	14
2.3	Summarisation of NDV encoded proteins and its functions	25
4.1	Purified mAbs concentration and titre	54
4.2	Molecular weight size (kDa) of IgG fragments from selected mAbs	58
4.3	Haemagglutination-inhibition and Haemolysis-inhibition tests	62
4.4	Cross-reactivity test for NDV inter-strains	64
4.5	Cross-reactivity test for avian viruses	65

LIST OF FIGURES

Figure	Page
2.1 Flow diagram on the protocol of generation of monoclonal antibodies	9
2.2 Flow diagram on hybridoma selection	12
2.3 Schematic diagram of the virion structure of Newcastle disease virus	24
3.1 Schematic diagram of antibody isotyping determination	44
4.1 Balb/c antiserum titres throughout the immunisation period	50
4.2 Proliferation of single hybridoma into high density colony	52
4.3 Absorbance values of selected mAbs after each limiting dilution	53
4.4 Isotyping classes and subclasses of selected mAbs	56
4.5 IgG heavy and light chains of selected mAbs	57
4.6a NDV protein profile	60
4.6b Immunoblotting against selected mAbs	60

LIST OF ABBREVIATIONS

ABTS	2, 2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium
ADCC	antibody-dependent cell-mediated cytotoxicity
AEV	avian encephalomyelitis virus
AIV	avian influenza virus
AP	alkaline phosphatase
APS	ammonium persulfate
BCIP	5-bromo-4-chloro-3-indolyl phosphate
BSA	bovine serum albumin
°C	Celsius
CAV	chicken anaemia virus
CD	cluster of differentiation
cm	centimetre
CMV	cytomegalovirus
CO ₂	carbon dioxide
dH ₂ O	distilled water
DMEM	Dulbecco's Modified Eagle's Medium
DMSO	dimethylsulfoxide
DNA	deoxyribonucleic acid
dTMP	deoxythymidine monophosphate
EBV	Epstein-Barr virus
EDTA	ethylenediaminetetraacetic acid
ELISA	enzyme-linked immunosorbent assay
F	fusion (glycoprotein)

FACS	fluorescence activated cell sorter
F _c	fragment crystallisable (Ig)
FCS	foetal calf serum
FPV	fowl pox virus
<i>g</i>	force of gravity
g	gram
gp120	glycoprotein 120 (HIV)
h	hour
H ₂ O ₂	hydrogen peroxide
HA	haemagglutination
HAT	hypoxanthine, aminopterin and thymidine
HAU	haemagglutination unit
HBV	hepatitis B virus
HCV	hepatitis C virus
HFCS	hybridoma fusion and cloning supplement
HGPRT	hypoxanthine guanine phosphoribosyl transferase
HI	haemagglutination-inhibition
HIU	haemagglutination-inhibition unit
HIV	human immunodeficiency virus
HLI	haemolysis-inhibition
HN	haemagglutinin-neuraminidase (glycoprotein)
HPLC	high performance liquid chromatography
HRP	horseradish peroxidase
HSV-1	herpes simplex virus -1
HSV-2	herpes simplex virus -2

HT	hypoxanthine and thymine
IBDV	infectious bursal disease virus
IBND	bivalent vaccines of IBV and NDV
IBV	infectious bronchitis virus
ICPI	intracerebral pathogenicity index
Ig	immunoglobulin
ILTV	infectious laryngotracheitis virus
im	intramuscular
IMP	inosine monophosphate
ip	intraperitoneal
iv	intravenous
IVPI	intravenous pathogenicity index
kb	kilobase
L	large (protein)
µg	microgram
µL	microlitre
µm	micrometre
M	matrix (protein)
M	molar
mA	milliampere
mAb	monoclonal antibody
mAbs	monoclonal antibodies
mg	milligram
min	minute (time)
mL	millilitre

mm	millimetre
mM	millimolar
MOPC	mineral oil plasmacytoma
NA	neuraminidase
NBT	nitro-blue tetrazolium chloride
ND	Newcastle disease
NDV	Newcastle disease virus
NEAA	non-essential amino acids
NI	neutralisation index
nm	nanometre
nM	nanomolar
NP	nucleoprotein
NT	neutralisation titre
NTE	sodium Tris EDTA
P	phosphoprotein
pAbs	polyclonal antibodies
PBS	phosphate buffered saline
PBST	phosphate buffered saline – Tween-20
PEG	polyethylene glycol
pg	picogram
pNPP	p-nitrophenyl phosphate disodium
RBC	red blood cell
RNA	ribonucleic acid
rpm	revolutions per minute
RSV	respiratory syncytial virus

RT	room temperature
RT-PCR	reverse transcription-polymerase chain reaction
s	second (time)
sc	subcutaneous
SDS	sodium dodecyl sulphate
SDS-PAGE	sodium dodecyl sulphate – polyacrylamide gel electrophoresis
TEMED	N, N, N', N'-tetramethylethylenediamine
TK	thymidine kinase
Tris	Tris-(hydroxymethyl)-aminomethane
UV	ultraviolet
V	volt
v/v	volume for volume
w/v	weight for volume

CHAPTER 1

INTRODUCTION

Newcastle disease (ND) is regarded throughout the world as one of the two most important diseases of poultry and other birds, the other disease being the highly pathogenic avian influenza. Its etiologic agent, the Newcastle disease virus (NDV), is a member of the family *Paramyxoviridae* and has been assigned to the genus *Avulavirus* in the subfamily *Paramyxovirinae* (Mayo, 2002; Peeters and Koch, 2002). Alexander (1989) had grouped NDV into five pathotypes based on their pathogenic signs: (1) viscerotropic velogenic NDV which causes hemorrhagic lesions in the gut; (2) neurotropic velogenic NDV shows respiratory and neurological signs but no gut lesions; (3) mesogenic NDV produces low mortality with acute respiratory disease and nervous signs in some birds; (4) lentogenic NDV shows mild and in apparent respiratory infections and (5) asymptomatic enteric NDV, avirulent viruses that appear to replicate primarily in the intestinal tract. Regardless of outbreaks or farms under constant surveillance, lack of obvious clinical signs or field experts will require confirmatory diagnosis for further identification and characterisation of the virus.

Diagnosis of ND started from the conventional techniques including virus isolation; *in vivo* estimation of pathogenicity through intracerebral pathogenicity index (ICPI) and intravenous pathogenicity index (IVPI) in one day old chicks and six weeks old chickens, respectively (Alexander, 1988); *in vitro* studies on the fusion protein cleavage site (Aldous and Alexander, 2001) and serological

tests like haemagglutination (HA) test and haemagglutination-inhibition (HI) test. These conventional methods are perceived as slow, laborious and required *in vivo* techniques. Since NDV has a 15.19 kb single-stranded negative RNA genome, reverse transcription-polymerase chain reaction (RT-PCR) was used to amplify the specific gene region using universal primers, and pathotype-specific primers or nested PCR (Aldous and Alexander, 2001). Real-time PCR that can detect minute amount (10 pg) of DNA (Tan *et al.*, 2004) and biopanning with a fusion phage that carried specific amino acid sequence to interact with surface glycoproteins (Ramanujam *et al.*, 2004) have also been performed.

Besides molecular-based techniques, monoclonal antibodies (mAbs) were intensively used in identification and differentiation of NDV strains [Iorio and Bratt, 1983 (Australia-Victoria strain); Nishikawa *et al.*, 1983 (D₂₆); Russell and Alexander, 1983 (Ulster 2C); Ishida *et al.*, 1985 (Miyadera and Taka); Abenes *et al.*, 1986 (Sato); Erdei *et al.*, 1987 (La Sota); Yusoff *et al.*, 1988 (Beaudette C); Jestin *et al.*, 1989 (Ploufragan); Panshin *et al.*, 1999 (Israel)]. MAbs were employed to study the antigenic differentiation among strains where single amino acid changes at the directed epitope can be detected (Chambers *et al.*, 1988; Yusoff *et al.*, 1989). The mAb era began in 1975 with a report in Nature by Kohler and Milstein entitled 'Continuous cultures of fused cells secreting antibody of predefined specificity'. It was reported that they could fuse immortalized myeloma cells with splenocytes which secreted a specific antibody of interest. The cell line that produces such antibodies is termed hybridoma. Since then, mAbs have become increasingly valuable in both research and therapeutic applications. The usefulness of mAbs can be characterised into three

main points: their specificity of binding, their homogeneity and their ability to be produced in unlimited quantities (Harlow and Lane, 1988). Since the antibodies produced are from one specific hybridoma cell, their identical properties make them very powerful in their ability to detect any specific epitope. Alexander *et al.* (1997) had allocated over 1500 NDV into different groups based on their ability to react with different panels of mAbs. MAbs have also been used to distinguish vaccine viruses from epizootic viruses in a given area (Srinivasappa *et al.*, 1986). Nevertheless, it is very difficult to obtain mAbs which are specific to NDV commercially. Therefore, the objectives of this study are:

- a) to generate a panel of murine monoclonal antibodies against NDV strain AF2240 and
- b) to characterise the selected hybridoma clones.

CHAPTER 2

LITERATURE REVIEW

Kohler and Milstein (1975) had successfully developed a technique that allows the growth of cells secreting antibodies with a defined specificity. In this technique the splenocytes isolated from an immunised animal, is fused with myeloma cells, a type of tumour cell. These hybrid cells or better known as hybridomas can be cultured *in vitro*. Antibodies secreted from hybridomas are known as monoclonal antibodies (mAbs).

2.1 Basic Concepts in Hybridoma Technology

2.1.1 Somatic Cell Hybridisation

The techniques of somatic cell fusion used by Kohler and Milstein (1975) to generate hybridomas secreting anti-sheep red blood cell with inactivated Sendai virus was a breakthrough in the field of cell biology. Cell fusion between lymphocytes and myelomas was associated with the presence of Sendai virus fusion glycoprotein, making it possible for their membrane to coalesce, cytoplasm to intermingle and multinucleated homokaryons and heterokaryons were formed (Gordon, 1975). Thus, different viruses with surface glycoproteins such as Semliki Forest virus, vesicular stomatitis virus, fowl plaque virus and influenza virus (White *et al.*, 1980, 1981) were applied to study cell fusion mechanisms. Another breakthrough was using Epstein-Barr virus (EBV) to fuse

human peripheral blood lymphocytes with human plasmacytomas to generate human mAbs (Roder, 1986).

The tumour caused by malignantly transformed antibody secreting cells is known as myeloma or plasmacytoma. According to Goding (1996), pathologists may make a morphological distinction between these terms but they may be regarded as biologically identical. Mineral oil or pristane were found to be potent inducers of myeloma in Balb/c mouse. Myelomas that were isolated using this approach were termed mineral oil plasmacytoma (MOPC) (Potter and Boyce, 1962; Potter, 1972). Myelomas that are used as fusion partners should not produce antibodies to avoid production of hybridomas that secrete more than one type of antibody. Harlow and Lane (1988) have recommended the following cell lines as good fusion partners and were successfully being used in the cited articles: FO (Davis *et al.*, 1982; Mao and France, 1984); FOX-NY (Lane, 1985); NS1/1-Ag4-1 (Nishikawa *et al.*, 1983; Russell and Alexander, 1983; Yusoff *et al.*, 1988; Llamas *et al.*, 2000); Sp2/0-Ag14 (Iorio and Bratt, 1983; Long *et al.*, 1986; Letellier *et al.*, 2001; Fontes *et al.*, 2005) and X63Ag8.653 (Davis *et al.*, 1982; Srinivasappa *et al.*, 1986).

Splenocytes are obtained from the immunised mouse through splenectomy. A spleen from an immunised mouse contains approximately 5×10^7 to 2×10^8 splenocytes (Harlow and Lane, 1988). Marusich (1988) reported that 1×10^5 splenocytes were sufficient to generate hybridomas. Hybridoma cells are created by fusing splenocytes from an immunised animal with myeloma cells to enable the hybridomas to possess both the antibody secreting properties of the parent